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USING transplantation methods, several authors have shown that sarcomas
induced by methylcholanthrene (MC) can elicit an immune response in syngeneic
hosts (Foley, 1953; Prehn and Main, 1957; Revesz, 1960: Old et al., 1962), or even
in the autochthonous host (Klein et al., 1960). Immunity to the tumour is usually
induced by transplanting the tumour to syngeneic hosts and allowing the animals
to grow tumours which are then excised, or have their blood supply strangulated.
Subsequent challenge of these pre-immunised hosts is made with viable cells from
the same original tumour which has been maintained by passage in other syngeneic
animals. The degree of antigenicity of a tumour can be measured by the diffi-
culty with which immunity to it can be broken down.
Old et al. (1962), in a study of 11 MC-induced sarcomas found that the first
four tumours to appear were highly antigenic, while some of those with longer
latent periods had little or no demonstrable antigenicity. As a result of these
findings, they proposed that the latent period of carcinogenesis is a selection period
in which cells with neoplastic potential appear very early but, being so highly
antigenic, they are promptly destroyed by the host. Tumours appear when the
growth potential of the altered cells succeeds in over-riding any immunological
response of the host. Later tumours, arising from cells which had been subjected
to a longer period of immunological selection, would tend to be less antigenic.
If this immunological selection theory of MC carcinogenesis holds good, it
would be expected that tumours arising in animals which had been subjected to
long-term immune impairment might be more antigenic than those arising in
normal animals. Two recent investigations have shown that early thymectomy
of mice, which leads to permanent immunological impairment, does indeed cause
the appearance of more highly antigenic sarcomas than in normal mice following
MNC injection (Balner and Dersjant, 1966; Johnson, 1968). Moreover, the latter
author was able to show a decline in antigenicity of tumours as the latent period
increased, in both intact and thymectomised animals.
The reports of Maisin (1963, 1964) that regular thymus grafting during the
leriod ofcarcinogenesis appeared to increase the resistance of mice to skin tumour
induction by MC, as opposed to the generally reported decrease of resistance to
chemical induction of tumours in thymnectomised animals (Miller et al., 1963;
Grant and Miller, 1965; Nishizuka et al., 1965; Johnson, 1968), appeared to
indicate that regular thymus grafting had the reverse effect of thymectomy on
chemical carcinogenesis. Maisin considered that some kind ofhormonal influence
of the grafted thvmus tissue helped to restore the immune response which hadJUNE MARCHANT
been depressed by the carcinogen and the host was thereby better able to recognise
the abnormal antigenicity of developing tumour cells and to promote their
immunological destruction. It follows from this line of reasoning that tumours
arising in thymus-grafted (immune repaired) animals should be less antigenic than
those arising in normal animals. Antigenic tests were therefore carried out on the
MC-induced sarcomas in thymus-grafted and control animals which were the
subject of the preceding communication (Marchant, 1969).
MATERIALS AND METHODS
Tunmoars
Male and female F1 (C57BL x IF) mice were given a subcutaneous injection
of 1 mg. of3-methylcholanthrene (MC) in olive oil on the right flank when 3 months
old. Half of the animals also received a subcutaneous graft of a whole thymus
gland once a fortnight, beginning 5 weeks before the MC injection. The grafts
came from 6- to 10-day-old syngeneic donors of the same sex. Sarcomas arose in
22 of 24 animals.
The antigenicity test
For each tumour the test depended on a comparison of the growth of known
numbers of viable tumour cells in actively immunised syngeneic hosts witlh the
growth of similar doses in normal control animals.
Preparation of tumour cell suspensions
All operations were carried out under sterile conditions. When the sarcomas
were 1.0 to 2'0 cm. in diameter, the mice were killed and the tumours removed
aseptically. They were minced with scissors and washed in Dulbecco " A "
phosphate-buffered saline (Oxoid) with 100 ,ug. Streptomycin Sulphate B.P.
(Glaxo) and 100 i.u. Sodium Benzvl Penicillin (Glaxo) per ml. The minced
tumour was then transferred to a bottle containing a magnet and about 15 ml.
0*25 per cent trypsin (Difco) containing 0-2 mg. Deoxyribonuclease (BDH) per
ml. It was then placed on a magnetic stirrer and incubated at 370 C. for half-an-
hour, following which the suspended cells were removed and washed twice bv
gentle centrifugation. Cell clumps were sometimes removed by filtration through
a fine web of glass wool. The number of viable cells in the final suspension was
estimated in a haemocytometer by their ability to exclude eosin. The cell con-
centration was then adjusted to give the appropriate concentration of live tumour
cells for subcutaneous injection, the volume of fluid injected being kept constant
at 0.1 ml.
Design of the test
The design ofthe test for antigenicity is represented in Fig. 1. (Three tumours
which were growing very poorly in their original hosts were passaged once before
the test was commenced, in order to obtain sufficient material.)
Stage 1. About 6 to 12 syngeneic mice of the same sex as the tumour donor
were injected subcutaneously on the right flank with 2 x 105 live tumour cells in
0*1 ml. saline.
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Stage 2. Two animals in which tumour was growing were put aside to serve
as intermediary hosts providing a reservoir of tumour material. The remaining
animals had their tumours excised when they reached a size of approximately
1*0 cm. diameter. These served as immunised animals.
Stage 3.-Two to 3 weeks after excision oftumour from the immunised animals,
an intermediary host of the same tumour was killed and a tumour cell suspension
* -' 4t
STAGE I
STAE 2
F.1. Design of test fo sacm antg t.
FlG. I.-Design of test for sarcoma antigenicity,.
prepared. Each immunised animal, and a similar number of unimmunised
syngeneic mice of the same sex and age, were injected subcutaneously with three
cell doses at different sites. (It was considered that challenge with three different
doses would yield more information than the more usual challenge with a single
dose but, because insufficient animals were available for single doses to be tested
in single recipients, three different doses were given to each individual.) The cell
doses injected were 2 x 105 on the chin, 2 X 104 on the left flank and 2 x 103 in
the centre back.
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Assessrment of antigenicity
Mice were palpated twice weekly and the tumour growth at each site recorded.
The latent period was judged as the number of days to the first record of a con-
tinuously growing lump. Immunised animals in which regrowth occurred at the
original immunising site on the right flank were rejected. Because growth of the
highest cell dose frequently rendered it necessary to kill host animals before much,
if any, activity had occurred at the sites ofinjection ofthe lower cell dose, only the
data relating to the inhibition of growth of the highest cell dose in actively
immunised animals was utilised. A value for the antigenicity of the tumour was
obtained by calculating the percentage inhibition of growth at the site challenged
with 2 x 105 cells in pre-immunised animals compared with controls. It is
expressed as the ratio:
Mean latent period in control mice- Mean latent period in pre-immunised mice 100
Mean latent period in control mice
RESULTS
Of the 24 thymus-grafted and control animals, 22 animals developed sarcomas
(Marchant, 1969) and 19 of these were tested for antigenicity in the described
manner. Table I shows the growth of the first inoculum of 2 x 105 cells (Stage 1
TABLE I. Growth of First Imrnmunising Inoculum of 2 x 105 Live Sarcoma Cells
in Syngeneic Hosts of the Same Sex as the Tumour Donor. (Stage 1 of the
Antigenicity Test)
Per cent " takes"
Number of , _ ___
Sex Thymus grafted sarcomas tested 100 80- 60- 40- 20-
F . + 3 1 0 0 1 1
F. 4 4 0 0 0 0
l . + 6 . 5 1 0 0 0
A -. 6 5 1 0 0 0
of the antigenicity test) from these 19 sarcomas. Fifteen sarcomas grew in all
recipients, but two of three tumours tested from female donors receiving thymus
grafts grew very poorly. One of these (4078, Table II) was later proved to be
highly antigenic, while the other (4074) died out. The latter is estimated to be
highly antigenic also.
Table II shows the calculated antigenicities of the individual sarcomas and
gives data concerning latent period of induction, sex, thymus grafting and occur-
rence of localised swelling preceding tumour growth. With tumours 4087 and
4094, no control mice were challenged at stage III in the test, but an estimated
antigenicity value was based on comparison of the growth rate of 2 x 105 cells
in the triply challenged immunised animals with the growth rate of the original
immunising dose in the same animals, which was also 2 x 105 cells. (This
comparison is likely to give a slight underestimate of the antigenicity, for in the
cases of all the other tumours the single immunising dose of 2 x 105 cells never
grew more rapidly than 2 x 105 cells in the triply inoculated control animals.)
As will be seen from Table II, antigenicity values of sarcomas in thymus
grafted animals were not lower than those in control animals. On the contrary,
the mean antigenicity value of tumours in thymus-grafted males was 70 5, while
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TABLE II.-Antigenicity of MC-indluoed Sarcomas in Male and Female F1
(C57BL x IF) Mice With, and Without, Fortnightly Grafts of Isoloqous
Thymus Glands
Thymus Swelling preceding
Sex grafts tumour growth
F. +
F. +
F. +
F. +
F . + . ++
F. + +
M +
M. + . +
M. +
M. +
M. +
M. +
F. -
F. - . ++
F. - . +
F. -
F. - . ++
F. - . +
M. - . +
M . -
M. - . +
M. - . +
M. - . +
M. - . +
F. +
F. _
M. +
M _
Latent period of
sarcoma induction
(weeks)
13k
11k
19
Died without @ 43
18
141
16
12
16
15i
12j
12
131
15
14j
Died without @ 261
18
19
13i
121
13k
19j
14*
16J
(of 5) 15
(of 5) 16
14
15
Antigenicity value
of sarcoma
(per cent inhibition)
Estimated 90+
Not tested
27
85
Not tested
97
Estimated 65
79
9
94
79
98
72
Not tested
12
Not tested
54
45
Estimated 20
73
36
27
(of 3) 67
(of 3) 61
70 5
42-5
that for control males was 42. These values did not differ significantly, however
(t 1-82, df 10, P 0.1). No correlation between high antigenicity and short
latent period was noted.
Table III records in some detail the " takes " of the three different-sized cell
inocula in pre-immunised and control hosts. It will be noted that the challenging
dose of 2 x 105 sarcoma cells grew in every single control animal. This usually
occurred in the second week after inoculation. In pre-immunised hosts only five
of the 17 sarcomas tested grew in all animals at this dose. Consultation of
Table II shows that these five tumours had the lowest antigenicity values, all
being below 30 per cent. Tumours with antigenicity values of over 80 per cent
grew in less than 50 per cent of pre-immunised hosts.
As can be seen from Table III, the lower cell doses grew in a larger proportion
of control animals than in pre-immunised hosts, but there were many animals of
both kinds in which the largest cell dose grew to a size which necessitated killing
the animal before any activity was discernible at the sites of injection of the two
lower doses. In the majority of animals in which growth of the lower cell doses
did take place, the rule was: the largest cell dose grew earliest, followed by the
intermediate dose and subsequently the lowest dose. However, a number of
exceptions to this " dosage rule " were found and are indicated in the table.
They occurred in 10 pre-immunised mice (with 7 of the 17 tumours) and in 20
control mice (inoculated with 10 different tumours). Most of these exceptions
were cases where growth of 2 x 105 cells was followed by growth of 2 x 103 cells,
Mouse
number
4074
4075
4076
4077
4078
4079
4086
4087
4088
4089
4090
4091
4080
4081
4082
4083
4084
4085
4092
4093
4094
4095
4096
4097
Mean
values
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while growth of 2 x 104 cells occurred later, or not at all. However, in four pre-
immunised hosts (marked by asterisks in Table III) no growth ofeither ofthe two
higher cell doses took place, but 2 x 103 cells eventually grew after a greatly
prolonged period of time (between 62 and 170 days).
DISCUSSION
The design ofthe antigenicity test used here proved too cumbersome to extend
to large numbers of tumours, for it involved frequent palpation and recording of
tumour growth on large numbers of mice at four separate sites (one immunising
and three challenging).
It is clear from Table II that sarcomas arising in thymus-grafted animals were
not less highly antigenic than those arising in control animals. The results ofthis
test did not support Maisin's (1964) suggestion that thymus grafting helps " to
restore the immune response depressed by the carcinogenic agent and by so doing
helps the host to recognise the abnormal antigenicity of the developing tumour
cells" and eliminate them. No correlation between high antigenicity and short
latent period could be detected in the present experiment either, so it does not
lend support to Old's hypothesis of carcinogenesis which was outlined in the
introduction. However, in the present experiment the time spread of latent
periods was small (11k to 191 weeks compared with Johnson's 8 to 25 weeks).
The use of a smaller dose of carcinogen might have resulted in a bigger spread of
latent periods and perhaps greater possibility of detecting a fall of antigenicity
with time.
Perhaps one of the most interesting results of the antigenicity test described
here is the fact that tumour growth from the different sized cell inocula given
simultaneously did not always follow the usual " dosage rule " in which outgrowth
of the largest inoculum was followed in turn by the intermediate and finally the
smallest (see Table III). In many individuals, smaller cell doses of these anti-
genic sarcomas fared better than larger doses. Old et al. (1962) described experi-
ments with 2 MC-induced sarcomas ofknown antigenicity in which very small cell
inocula sometimes grew into tumours in normal hosts more readily than cell
numbers 30 times greater. They considered the most likely explanation might be
that the antigenic stimulus from the smaller number of cells might be so slight
that these cells could establish themselves as a well-vascularised tumour mass
before exciting an immune response, while antigen from a larger number of cells
may be sufficient to initiate an efficient immune response during the process of
establishment, when the tumour is most vulnerable to immune attack. Klein
(1967) also holds this view about the phenomenon, which he describes as " sneaking
through ".
In the present experiments, however, the situation is somewhat different
because the small cell doses were injected at the same time as larger cell doses and
would surely be influenced by the immunological reaction mounted by the host
against the larger antigenic stimuli. Moreover, the four most extreme cases
(where growth of both the higher cell doses was completely suppressed and
growth of only the lowest cell dose took place) occurred in pre-immunised hosts.
This would seem to suggest that it may be related to the amount of circulating
antibody present and is reminiscent ofthe complex phenomenon ofimmunological
enhancement. To quote Kaliss (1966) this " phenomenon is characterised by the
progressive growth, or delayed rejection, of (tumour) allografts as a consequence
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of the host's active or passive immunisation against the graft; the presence of
humoral anti-graft antibody is its requisite ". By immunisation and appropriate
timing of two separate tumour grafts, Kaliss has been able to demonstrate both
graft enhancement and accelerated rejection in the same animal.
The requirements for enhancement are rather stringent, the chief of which is
a " readily enhanceable " tumour. This factor depends on relative susceptibility
to cytotoxic isoantiserum, which may in turn be influenced by tumour cell to
antibody ratios. So far as the author is aware, however, enhancement has only
been described for grafts exchanged between strains having different transplanta-
tion antigens, whereas in the present experiments hosts and donors were isogeneic
and any immunological explanation of the results must rest upon tumour specific
antigens.
The fact that small inocula of isogeneic tumour cells were able to survive and
grow into tumour in some individuals, in which larger cell inocula failed to grow,
is of importance in consideration of metastasis or attempts at immunotherapy.
SUMMARY
Sarcomas induced by 3-methycholanthrene in F1 (C57BL x IF) male and
female mice receiving fortnightly syngeneic thymus grafts were tested for anti-
genicity and compared with MC-induced sarcomas in normal animals. For each
antigenic test, three different-sized doses of viable tumour cells were injected
simultaneously into pre-immunised and normal syngeneic hosts and inhibition of
growth in the former was assessed.
All tumours showed some inhibition of growth in pre-immunised hosts, but
sarcomas appearing in thymus-grafted animals were not less antigenic than those
appearing in control animals. No fall in antigenicity with length of latent period
was demonstrated.
In a small number of both pre-immunised and normal isologous hosts, smaller
cell inocula grew better than a cell dose 10, or even 100, times greater.
This work was supported by the Birmingham Branch of the British Empire
Cancer C/ampaign for Research.
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